Cellectar Biosciences (CLRB) Stock Forecast, Price Target & Predictions
CLRB Stock Forecast
Cellectar Biosciences stock forecast is as follows: an average price target of $12.00 (represents a 491.13% upside from CLRB’s last price of $2.03) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CLRB Price Target
The average price target for Cellectar Biosciences (CLRB) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 491.13% upside from CLRB's last price of $2.03.
CLRB Analyst Ratings
According to 1 Wall Street analysts, Cellectar Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CLRB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cellectar Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 28, 2024 | Jeff Jones | Oppenheimer | $12.00 | $3.63 | 230.12% | 491.13% |
The latest Cellectar Biosciences stock forecast, released on Mar 28, 2024 by Jeff Jones from Oppenheimer, set a price target of $12.00, which represents a 230.12% increase from the stock price at the time of the forecast ($3.63), and a 491.13% increase from CLRB last price ($2.03).
Cellectar Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $2.03 | $2.03 | $2.03 |
| Upside/Downside | -100.00% | -100.00% | 491.13% |
In the current month, the average price target of Cellectar Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cellectar Biosciences's last price of $2.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Cellectar Biosciences's last stock rating was published by Oppenheimer on May 14, 2024. The company gave CLRB a "Outperform" rating, the same as its previous rate.
Cellectar Biosciences Financial Forecast
Cellectar Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $8.33K | $30.97K | - | - |
| Avg Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $12.00K | $30.00K | $7.40K | $12.58K |
| High Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $14.40K | $36.00K | $8.88K | $15.10K |
| Low Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $9.60K | $24.00K | $5.92K | $10.07K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 1.03% | - | - |
Cellectar Biosciences's average Quarter revenue forecast for Mar 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. CLRB's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $8.33K (Mar 10).
Cellectar Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.38M | $-1.81M | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.21M | $-4.20M | $-953.85K |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.77M | $-3.36M | $-763.08K |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.65M | $-5.04M | $-1.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | - | - |
0 analysts predict CLRB's average Quarter EBITDA for Mar 24 to be -, with a high of - and a low of -. This is -100.00% lower than Cellectar Biosciences's previous annual EBITDA (Mar 10) of $5.38M.
Cellectar Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $5.35M | $-1.81M | - | - |
| Avg Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-12.36M | $-11.98M | $-14.48M | $7.70M | $-2.22M | $-4.21M | $-954.87K |
| High Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-9.18M | $-11.98M | $-14.48M | $9.25M | $-1.77M | $-3.36M | $-763.90K |
| Low Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-15.18M | $-11.98M | $-14.48M | $6.16M | $-2.66M | $-5.05M | $-1.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.82% | - | - |
Cellectar Biosciences's average Quarter net income forecast for Mar 24 is $-14.48M, with a range of $-14.48M to $-14.48M. CLRB's average Quarter net income forecast represents a -370.60% decrease compared to the company's last Quarter net income of $5.35M (Mar 10).
Cellectar Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $644.76K | $476.20K | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cellectar Biosciences's average Quarter SG&A projection for Mar 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CLRB last annual SG&A of $644.76K (Mar 10).
Cellectar Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $161.84K | $-235.40K | - | - |
| Avg Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.33 | $-0.32 | $-0.49 | $-220.32K | $-336.60K | $-235.62K | $-122.40K |
| High Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.25 | $-0.32 | $-0.49 | $-176.26K | $-269.28K | $-188.50K | $-97.92K |
| Low Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.41 | $-0.32 | $-0.49 | $-264.38K | $-403.92K | $-282.74K | $-146.88K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.73% | 0.70% | - | - |
According to 0 Wall Street analysts, Cellectar Biosciences's projected average Quarter EPS for Mar 24 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -100.00% decrease compared to CLRB previous annual EPS of $161.84K (Mar 10).
Cellectar Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CLRB | Cellectar Biosciences | $2.03 | $12.00 | 491.13% | Buy |
| LUMO | Lumos Pharma | $4.42 | $16.50 | 273.30% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| CAPR | Capricor Therapeutics | $18.60 | $35.75 | 92.20% | Buy |
| BNTC | Benitec Biopharma | $10.80 | $20.33 | 88.24% | Buy |
| BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
| LBPH | Longboard Pharmaceuticals | $59.50 | $61.00 | 2.52% | Hold |
CLRB Forecast FAQ
Is Cellectar Biosciences a good buy?
Yes, according to 1 Wall Street analysts, Cellectar Biosciences (CLRB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CLRB's total ratings.
What is CLRB's price target?
Cellectar Biosciences (CLRB) average price target is $12 with a range of $12 to $12, implying a 491.13% from its last price of $2.03. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cellectar Biosciences stock go up soon?
According to Wall Street analysts' prediction for CLRB stock, the company can go up by 491.13% (from the last price of $2.03 to the average price target of $12), up by 491.13% based on the highest stock price target, and up by 491.13% based on the lowest stock price target.
Can Cellectar Biosciences stock reach $3?
CLRB's average twelve months analyst stock price target of $12 supports the claim that Cellectar Biosciences can reach $3 in the near future.
What are Cellectar Biosciences's analysts' financial forecasts?
Cellectar Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.5M (high $15.5M, low $15.5M), average EBITDA is $0 (high $0, low $0), average net income is $-35.574M (high $-35.574M, low $-35.574M), average SG&A $0 (high $0, low $0), and average EPS is $-0.95 (high $-0.95, low $-0.95). CLRB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $79M (high $79M, low $79M), average EBITDA is $0 (high $0, low $0), average net income is $-9.736M (high $-9.736M, low $-9.736M), average SG&A $0 (high $0, low $0), and average EPS is $-0.26 (high $-0.26, low $-0.26).
Did the CLRB's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2010), Cellectar Biosciences's revenue was $8.33K, missing the average analysts' forecast of $12K by -30.55%. The company's EBITDA was $5.38M, beating the average prediction of $0 by 0%. Cellectar Biosciences's net income was $5.35M, missing the average estimation of $7.7M by -30.56%. The company's SG&A was $644.76K, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $161.84K, missing the average prediction of $-220K by -173.46%